GCB helps spin out success

GCB logo, no words
GCB News

GCB helps spin out success

In FY20, 17 new start-up companies formed at Duke, according to Duke’s Office of Licensing and Ventures (OLV).

Xilis is headed by GCB members David Hsu, M.D, Ph.D. and Xiling Shen, Ph.D. The company is developing next-generation micro-organosphere technology to guide precision therapy for cancer patients and accelerate drug discovery.

The Proteomics and Metabolomics Core Facility have provided their services to several of the PIs who spun out companies in FY 20 as well. 

OLV oversees the management of innovations resulting from Duke research – from creation, to feasibility and marketing, to protection, and on into licensing to commercial partners, for both startups and existing companies.

Read OLV’s Annual Report for more information

Related News

Anne Yoder and Purushothamma Rao Tata

GCB Welcomes New Members

This fall, GCB welcomed two new members: Anne Yoder, Ph.D., and Purushothama Rao Tata, Ph.D.

artistic rendering of red blood cells

Incorporating Genomics into Lymphoma Classification Can Improve Care

By Lynne Lederman, Ph.D. - Targeted Oncology

blue paint peeling off a building

Childhood Lead Exposure Leads to Structural Changes in Middle-aged Brains

Study participants had lead exposures typical for the 1970s

By Karl Leif Bates